Novel Strategy to Fabricate PLA/Au Nanocomposites as an Efficient Drug Carrier for Human Leukemia Cells in Vitro
© Li et al. 2010
Received: 3 July 2010
Accepted: 14 August 2010
Published: 14 September 2010
Poly (lactic acid) (PLA) polymer has the promising applications in the biomedical field because of its biodegradability and safe elimination. In this study, we have explored the bio-application of new nanocomposites composed with PLA nanofibers and Au nanoparticles as the potential drug carrier for an efficient drug delivery in target cancer cells. The results demonstrated that the anticancer drug daunorubicin could be efficiently self-assembled on the surface of PLA/Au nanocomposites and the synergistic enhancement of PLA/Au nanocomposites conjugated with daunorubicin into drug-sensitive K562 and drug-resistant leukemia K562/AO2 cells could be obviously observed by MTT assay and confocal fluorescence microscopy studies. These observations suggest that the new nanocomposites could readily induce daunorubicin to accumulate and uptake in target leukemia cells and increase the drug's cytotoxicity. Especially, the PLA/Au nanocomposites could significantly facilitate the cellular drug absorbtion of daunorubicin into drug-resistant K562/AO2 cells and efficiently inhibit the cancer cell proliferation. This raised the possibility to utilize the PLA/Au nanocomposites as a new effective additive agent to inhibit the drug resistance and thus as a novel strategy to sensitively track the respective cancer cells.
KeywordsHuman leukemia PLA/Au nanocomposites Daunorubicin Drug delivery Multidrug resistance
As one of the difficult treated diseases, cancer threats the life of many patients. To reduce the morbidity and mortality of cancer, early diagnosis and cancer systemic therapies are of paramount importance. The cure efficiency of cancer chemotherapy depends not only on the anticancer drug itself but also on how the drug reagent is efficiently delivered to its targets . Although there is much effort to solve the relevant problems, it is still a big challenge to develop a new strategy to mark and track the target cancer cells for the early diagnosis and cure of cancers. Besides, the emergence of drug resistance is a worldwide puzzle in the related diseases' therapies, while the occurrence of the multidrug resistance (MDR) phenomenon is one of the major obstacles to the success of the tumors' chemotherapy [2, 3]. It is noted that the mechanisms involved in drug resistance of cancer cells are pertaining to multifactor processes. And the cellular uptake of some drugs may be poor by the mutated tumor cells. The proteins related with drug resistance may pump out the drug molecules from the mutated tumor cells, which will decrease the drug concentration inside the tumor cells . Thus, the efficient targeting of drug delivery for relevant cancer cells could afford a new strategy for the effective treatment of targeted cancers [5, 6].
Recently, some reports have demonstrated that anticancer drugs could be readily modified on the biocompatible nanomaterials covalently or non-covalently, which could afford the sustained drug delivery for the target cancer cell lines and reduce the relevant toxicity toward normal cells and tissues [7–9]. For instance, some semiconductor nanoparticles such as TiO2 nanoparticles can penetrate across barriers into cancer cells to allow efficient drug accumulation at the targeted locations, which could have promising application in biomedical and bioengineering fields due to its oxidizing and biocompatible properties, chemical inertness and photoactivity [10–16]. Au nanoparticles were also applied as a potential carrier or protective container for biologically active agents . With the characteristics of biocompatibility, biodegradability and absorbability, some polymers have been widely used in medical research such as DNA binding delivery with PLA/PEG nanoparticles, poorly soluble Ethaselen's delivery with mPEG-PLA copolymers, prostheses for tissue replacements, supporting surgical operation and artificial organs for temporary or permanent assistance [17–19]. Some biocompatible polymer can also act as drug carriers by controlling the release rate of the loaded drug [20–23]. Meanwhile, the blends of the biodegradable polymers have been explored for the potential applications in biomedical field such as the drug release/implants for orthopedic surgery or blood vessels due to their good biocompatibility, low cost, safe elimination, lightweight and high performance [24–29]. Thus, on the basis of these observations, the biodegradable poly(lactic acid) (PLA) nanofibers have been fabricated in this study by using electrospinning and then adopted to blend with Au nanoparticles to form a new nanocomposites with the good biocompatibility. Afterward, the PLA/Au nanocomposites were further conjugated with anticancer drug daunorubicin to efficiently facilitate the intracellular accumulation of the anticancer agents inside drug-sensitive and drug-resistant leukemia cells.
Daunorubicin was purchased from Nanjing Pharmacy Factory (analytical grade) and freshly prepared with phosphate buffer solution (PBS, 0.1 M, pH 7.2). Au nanoparticles were freshly prepared according to the previous report , in which 100 mL of 0.01% HAuCl4 was heated to boiling with uninterruptedly agitating and 3.0 mL of 1% trisodium citrate was dropped into the above solution. The system was continually agitated about 30 min until the reaction color did not change. Ultrapure water was added in which the final volume was 100 mL and the diameter of Au nanoparticle was about 15 nm. The other reagents were analytical grade. For the following studies, all experimental measurements were performed at least three times in parallel.
The Preparation of Poly(lactic acid) Nanofibers
Poly(lactic acid) nanofibers were fabricated by electrospinning. First, the poly(lactic acid) (Mn = 340,000) was dissolved in the solvent of chloroform (10%, wt) and stirred for 2 h. Next, it was loaded into a syringe connected with anodal voltage. Aluminum foil as a collecting substrate was connected with cathodal voltage. Electrospinning was performed at room temperature with a gap between the substrate electrode and the tip of the capillary of 10 cm at driving voltages of 10 kV. The PLA nanofibers were characterized by scanning electron microscopy (Magnification: 10,000) as shown in our previous report .
The Preparation of PLA/Au Nanocomposites Conjugated with Dauborubicin
The aqueous suspension of PLA nanofibers was prepared in double-distilled water by ultrasonic treatment for about 20 min. Then, Au (2.80 × 10-7 mol/L) and PLA nanofiber gel aqueous solutions (1.3 × 10-3 g/L) were mixed and incubated together for more than 12 h to form the PLA/Au nanocomposites. The solution of daunorubicin (3.3 × 10-4 mol/L) was mixed into the nanocomposites and stored in the dark at 4°C for more than 12 h to form the PLA/Au nanocomposites conjugated with dauborubicin.
Atomic Force Microscopy Study
In a relevant atomic force microscopy study (AFM), 5 μL from the aforementioned different solutions was deposited onto freshly cleaved mica (already glued on a steel disk) and incubated for 5 min. After the sample dried under a nitrogen stream, imaging was performed in tapping mode, by using a Nanoscope IIIa Multimode AFM (Digital Instruments, Santa Barbara, CA, USA) operating in air at room temperature.
For cell culture, human leukemia cells (K562 and K562/AO2) were cultured in a flask in an RPMI 1640 medium (GIBCO) supplemented with 10% fetal calf serum (FCS, Sigma), penicillin (100 mU/mL) and streptomycin (100 μg/mL) at 37°C in a humidified atmosphere containing 5% CO2, while 1 μg/mL doxorubicin was contained in the culture to maintain K562/AO2 cells' drug resistance in its daily culture.
The inhibition of cell growth was measured by MTT (Microculture Tetrazolium) assay. Initially, the respective leukemia cells (K562 and K562/AO2) in the log phase were seeded in a 96-well plate at a concentration of 1.0 × 104 cells) well. The target cells were treated with different concentration of PLA/Au nanocomposites, daunorubicin or daunorubicin conjugated with PLA/Au nanocomposites, respectively. Controls were cultivated with the respective solvent under the same conditions. Each culture was incubated for 48 h in a 5% CO2 incubators at 37°C, and then 20 μL of 5 mg/mL MTT was added to the wells and incubated for an additional 4 h. Subsequently, it was centrifuged at 1,000 rpm for 10 min and the supernatant was discarded, followed by the addition of 150 μL of dimethyl sulfoxide (DMSO) into each well and then incubated in the shaker at 37°C with gentle shaking about 5 min. Then, the optical density (OD) was read at a wavelength of 492 nm.
Laser Confocal Fluorescence Microscopy
The cell culture conditions were similar to those described above. Initially, the different cells were collected by centrifugation at 1,000 g for 5 min. Then, the supernatant solutions were discarded. The pellets were resuspended with PBS to eliminate the effect of medium in the fluorescence detection. And the cell suspension was detected on a Leica TCS SP2 (Leica). In the control experiments, only daunorubicin or PLA/Au nanocomposites were injected for relevant cellular incubation. The freshly prepared cell culture was dropped on a strictly cleaned glass plate immediately before the measurement. The excitation wavelength of fluorescence was 480 nm. All the optical measurements were carried out at room temperature (20 ± 2°C).
Results and Discussion
AFM Study of PLA/Au Nanocomposites Conjugated with Daunorubicin
Since the PLA nanofiber has a very high continuous surface area, it has attracted a great deal of attention in fabricating continuous ultrafine fibers or fibrous structures for various polymers, with typical examples including engineering plastics, biopolymers and polymer blends [32, 33]. From the specific nanostructure of the PLA nanofibers and the relevant nanocomposites observed in above AFM study, it is evident that the anticancer drug daunorubicin could be readily self-assembled on the surface of the new PLA/Au nanocomposites, which could be utilized as a new promising carrier for nanomedicine in cancer treatment.
Fluorescence Imaging of Intracellular Drug Delivery in Leukemia Cancer Cells
Additionally, our observations demonstrate that for drug-resistant K52/AO2 cells treated with DNR alone, scarce cancer cells with weak intracellular fluorescence could be observed. The very weak intracellular fluorescence of drug-resistant leukemia cells treated with DNR alone may be attributed to the over-expression of P-gp protein on the cell membrane of the drug-resistant cancer cells [34, 35], which could readily pump DNR molecules out of the relevant cancer cells so that much lower intracellular DNR fluorescence could be observed for K562/AO2 cells than that of K562 cells, as shown in Figure 4a and 4b. Interestingly, the presence of PLA/Au nanocomposites could efficiently facilitate the drug uptake of DNR into the drug-resistant leukemia cells and lead to the much higher intracellular drug concentration in the target cells, resulting in the remarkable enhancement of the intracellular fluorescence of drug-resistant leukemia cells (Shown in Figure 4b and 4f). This result suggests that the PLA/Au nanocomposites may affect the activity of P-gp protein and efficiently prevent the drug efflux from the drug-resistant leukemia cells. Thus, much more DNR could be readily permeated and accumulated into the relative cancer cells because the relevant synergistic effect of the PLA/Au nanocomposites could apparently inhibit the drug resistance of K562/AO2. In view of these observations, it appears that the PLA/Au nanocomposites may play as potential inhibitor of multidrug resistance (MRD) and thus efficiently promote the cellular uptake of the drug into the relevant drug-resistant cancer cells.
Cytotoxicity Study by MTT Assay
The resistant factors and reversal index of leukemia K562 and K562/AO2 cell lines to PLA/Au nanocomposites
Experimental (PLA/Au) group
In summary, in this study we have fabricated the new PLA/Au nanocomposites and explored the promising application of the PLA/Au nanocomposites to efficiently facilitate the uptake of anticancer drug in target cancer cells. Our observations demonstrate that the self-assembly and conjugation of anticancer drug DNR on the surface of PLA/Au nanocomposites could significantly enhance the drug accumulation into drug-sensitive K562 and drug-resistant leukemia K562/AO2 cells and thus increase the drug's cytotoxicity. Importantly, the PLA/Au nanocomposites could considerably reverse the multidrug resistance of K562/AO2 cells and efficiently inhibit the cancer cell proliferation. This raised the possibility to utilize the PLA/Au nanocomposites as a new effective additive agent to overcome the drug resistance and thus as a novel strategy to sensitively track the respective cancer cells for efficient cancer chemotherapy.
This work is supported by National Natural Science Foundation of China (90713023, 20675014 and 20535010), National Basic Research Program of China (No. 2010CB732404), the Chinese Ministry of Science and Technology (2007AA022007 and 2008DFA51180), the Natural Science Foundation of Jiangsu Province (BK2008149), Visiting Scholar Foundation of Key Laboratory of Biorheological Science and Technology (Chongqing University) and the Graduate Research and Innovation Program of Jiangsu Province (CX10B_083Z).
- Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS: Cancer Res. 2000, 60: 6641–6648.Google Scholar
- Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD: Cancer Res. 1995, 55: 5342–5347.Google Scholar
- Litman T, Nielsen D, Skovsgaard T, Zeuthen T, Stein WD: Biochim Biophys Acta. 1997, 1361: 147–158.View ArticleGoogle Scholar
- Song M, Guo DD, Pan C, Jiang H, Chen C, Zhang RY, Gu ZZ, Wang XM: Nanotechnology. 2008, 19: 165102. 10.1088/0957-4484/19/16/165102View ArticleGoogle Scholar
- Zhang RY, Wang XM, Wu CH, Song M, Li JY, Lv G, Zhou J, Chen C, Dai YY, Gao F, Fu DG, Li XM, Guan ZQ, Chen BA: Nanotechnology. 2006, 17: 3622–3626. 10.1088/0957-4484/17/14/043View ArticleGoogle Scholar
- Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A: Angew Chem Int Edit. 2005,44(39):6358–6362. 10.1002/anie.200501613View ArticleGoogle Scholar
- Peng T, Su J, Cheng SX, Zhuo RX: J Mater Sci Mater M. 2007,18(9):1765–1769. 10.1007/s10856-007-3022-9View ArticleGoogle Scholar
- Li JY, Wang XM, Wang CX, Chen BA, Dai YY, Zhang RY, Song M, Lv G, Fu DG: Chem Med Chem. 2007,2(3):374–378. 10.1002/cmdc.200600264View ArticleGoogle Scholar
- Bianco A, Kostarelos K, Partidos CD, Prato M: Chem Commun. 2005, 2: 571–577. 10.1039/b410943kView ArticleGoogle Scholar
- Schroeder U, Sommerfeld P, Ulrich S, Sabel BA: J Pharm Sci. 1998,87(11):1305–1307. 10.1021/js980084yView ArticleGoogle Scholar
- Paciotti GF, Kingston DG, Tamarkin L: Drug Develop Res. 2006, 67: 47–54. 10.1002/ddr.20066View ArticleGoogle Scholar
- Li JY, Wu CH, Gao F, Zhang RY, Lv G, Fu DG, Chen BA, Wang XM: Bioorg Med Chem Lett. 2006,16(18):4808–4812. 10.1016/j.bmcl.2006.06.069View ArticleGoogle Scholar
- Nie X, Leyland A, Matthews A: Surf Coat Tech. 2000, 125: 407–414. 10.1016/S0257-8972(99)00612-XView ArticleGoogle Scholar
- Ishihara T, Mizushima T: Expert Opin Drug Del. 2010,7(5):565–575. 10.1517/17425241003713486View ArticleGoogle Scholar
- Chen C, Lv G, Pan C, Song M, Wu CH, Guo DD, Wang XM, Chen BA, Gu ZZ: Biomed Mate. 2007, 2: L1-L4. 10.1088/1748-6041/2/4/L01View ArticleGoogle Scholar
- Wang L, Neoh KG, Kang ET, Shuter B, Wang SC: Biomaterials. 2010,31(13):3502–3511. 10.1016/j.biomaterials.2010.01.081View ArticleGoogle Scholar
- Zou WW, Liu CX, Chen ZJ, Zhang N: Nanoscale Res Lett. 2009,4(9):982–992. 10.1007/s11671-009-9345-3View ArticleGoogle Scholar
- Li XR, Yang ZL, Yang KW, Zhou YX, Chen XW, Zhang YH, Wang F, Liu Y, Ren LJ: Nanoscale Res Lett. 2009,4(12):1502–1511. 10.1007/s11671-009-9427-2View ArticleGoogle Scholar
- Jagur-Grodzinski J: Polym Advan Technol. 2006,17(6):395–418. 10.1002/pat.729View ArticleGoogle Scholar
- Ha CS, Gardella JA: Chem Rev. 2005, 105: 4205–4232. 10.1021/cr040419yView ArticleGoogle Scholar
- François F, Quinn DJ, Gilmore BF, McCarron PA, Scott cJ: Biomaterials. 2010,31(14):4214–4222. 10.1016/j.biomaterials.2010.01.143View ArticleGoogle Scholar
- Feng ZQ, Chu XH, Huang NP, Leach MK, Wang G, Wang YC, Ding YT, Gu ZZ: Biomaterials. 2010,31(13):3604–3612. 10.1016/j.biomaterials.2010.01.080View ArticleGoogle Scholar
- Hou ZQ, Wei H, Wang Q, Sun Q, Zhou CX, Zhan CM, Tang XX, Zhang QQ: Nanoscale Res Lett. 2009,4(7):732–737. 10.1007/s11671-009-9312-zView ArticleGoogle Scholar
- Eberhart RC, Su SH, Nguyen KT, Zilberman M, Tang L, Nelson KD, Frenkel P: J Biomat Sci Polym E. 2003, 14: 299–312. 10.1163/156856203321478838View ArticleGoogle Scholar
- Liao SS, Cui FZ, Zhang W, Feng QL: J Biomed Mater Res B. 2004,69(2):158–165. 10.1002/jbm.b.20035View ArticleGoogle Scholar
- Aou K, Kang S, Hsu SL: Macromolecules. 2005,38(18):7730–7735. 10.1021/ma051022eView ArticleGoogle Scholar
- Huda MS, Drzal LT, Misra M, Mohanty AK, Williams K, Mielewski DF: Ind Eng Chem Res. 2005,44(15):5593–5601. 10.1021/ie0488849View ArticleGoogle Scholar
- Jee KS, Park HD, Park KD, Kim YH, Shin JW: Biomacromolecules. 2004, 5: 1877–1881. 10.1021/bm049795iView ArticleGoogle Scholar
- Carlson D, Nie L, Narayan R, Dubois P: J Appl Polym Sci. 1999,72(4):477–485. 10.1002/(SICI)1097-4628(19990425)72:4<477::AID-APP3>3.0.CO;2-QView ArticleGoogle Scholar
- Zhang RY, Wang XM, He NY: J Nanosci Nanotech. 2005, 5: 1245–1248. 10.1166/jnn.2005.216View ArticleGoogle Scholar
- Lv G, He F, Wang XM, Gao F, Zhang G, Wang T, Jiang H, Wu CH, Guo DD, Li XM, Chen BA, Gu ZZ: Langmuir. 2008, 24: 2151–2156. 10.1021/la702845sView ArticleGoogle Scholar
- Teo WE, Ramakrishna SA: Nanotechnology. 2006, 17: 89–106. 10.1088/0957-4484/17/14/R01View ArticleGoogle Scholar
- Li D, Wang YL, Xia YN: Nano Lett. 2003,3(8):1167–1171. 10.1021/nl0344256View ArticleGoogle Scholar
- Roninson IB: Clin Physiol Biochem. 1987,5(3–4):140–151.Google Scholar
- Hu Z, Jin SK, Scotto KW: J Biol Chem. 2000, 275: 2979–2985. 10.1074/jbc.275.4.2979View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.